Structure Therapeutics develops life‐changing medicines for patients using advanced structure-based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions. Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company completed an initial public offering (IPO) in February 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location. Reporting to the SVP Tech Ops, the Senior Director, Drug Substance (Small Molecule) will be responsible for late-stage development, scale-up, validation, and commercial readiness of small-molecule drug substance. This leader will direct Late Stage, PPQ, and commercial launch activities and establish a robust technical and quality foundation for long-term product success. The role requires deep expertise in process chemistry, QbD, FMEA, and regulatory expectations, combined with extensive experience managing global CDMOs, CMOs, and CRO partners.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree